News
Ibrance cleared in US for 'double-positive' breast cancer
1+ hour, 50+ min ago (555+ words) Pfizer's Ibrance has become the first CDK4/6 inhibitor to be approved by the FDA for a challenging subtype of breast cancer that is often resistant to current treatment options. Ibrance (palbociclib) has been cleared for hormone receptor (HR)-positive, HER2-positive breast…...
Novartis snaps up PI3 K" breast cancer drug in $3bn deal
3+ mon, 5+ day ago (535+ words) Novartis has reached an agreement to buy a PI3 K-targeting drug for breast cancer from Synnovation Therapeutics, paying a hefty $2 billion upfront for the asset, which is in phase 1/2 testing. The deal, which includes another $1 billion potential milestone payments, will see…...
Denying prostate cancer screening 'no longer rational"
3+ mon, 1+ week ago (811+ words) A study comparing outcomes after prostate cancer and breast cancer screening has shown that both are effective at diagnosing cases, reducing deaths, and avoiding unnecessary harm. The analysis " reported at the European Association of Urology (EAU) annual congress in London,…...
Enhertu moves into frontline breast cancer treatment
6+ mon, 1+ week ago (564+ words) Daiichi Sankyo and Astra Zeneca's Enhertu has been cleared for previously-untreated HER2-positive breast cancer in the US, becoming the first new first-line option in more than a decade. The FDA approval of Enhertu (trastuzumab deruxtecan) in combination with Roche's Perjeta…...
Pfizer makes first-line case for Tukysa in breast cancer
6+ mon, 2+ week ago (538+ words) Pfizer's oral HER2 inhibitor Tukysa looks poised to find a new role as first-line maintenance therapy for HER2-positive metastatic breast cancer, based on now-revealed data from the HER2 CLIMB-05 study. The results, presented at the SABCS conference, show that the combination of…...
Roche extols 'unprecedented' result with breast cancer drug
7+ mon, 1+ week ago (541+ words) Roche's oral selective oestrogen receptor degrader (SERD) giredestrant has achieved what the company says is a stellar result in an early breast cancer trial, building on earlier data in more advanced disease. The topline readout of the lid ERA trial…...
Advances in breast cancer: What's new from ESMO 2025
7+ mon, 3+ week ago (441+ words) ESMO 2025 showcased the breadth and urgency of breast cancer research, which remains one of the most diagnosed malignancies worldwide, and its major subtypes: HR+, HER2+ and TNBC respond differently to treatment and develop resistance through distinct mechanisms. Another emerging strategy is…...
Roche's oral SERD comes good in 2nd-line breast cancer trial
9+ mon, 2+ day ago (534+ words) Roche has staked a claim to use its oral selective oestrogen receptor degrader (SERD) giredestrant as a second-line therapy for breast cancer, regardless of a patient's ESR1 mutation status. Top-line results from the ev ERA study showed that the combination of…...
From prostate cancer to breast cancer: In conversation with Christine Roth
10+ mon, 1+ week ago (168+ words) At ASCO 2025, Bayer announced new data from recent clinical trials that highlight significant advancements in both prostate cancer and women's health. Onsite for the Congress in Chicago, web editor Nicole Raleigh sat down with Christine Roth, executive vice president of…...
Meta harvested health data to target ads, jury concludes
10+ mon, 2+ week ago (516+ words) A jury in the US has found that tech giant Meta illegally compromised the privacy of a US woman who shared her data with a menstrual cycle and fertility tracking app. The class action lawsuit was filed with the US…...